Literature DB >> 25534527

Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.

Emanuela Taioli1, Andrea S Wolf2, Raja M Flores3.   

Abstract

BACKGROUND: This comprehensive meta-analysis was conducted to answer the question as to which procedure, pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP) is more beneficial to malignant pleural mesothelioma patients' outcome.
METHODS: Original research studies that evaluated long-term outcomes of P/D versus EPP were identified, from January 1990 to January 2014. The combined percent perioperative and 2-year mortality, and median survival were calculated according to both a fixed and a random effect model. The Q statistics and I(2) statistic were used to test for heterogeneity between the studies.
RESULTS: There were 24 distinct data sets, for a total of 1,512 patients treated with P/D, and 1,391 treated with EPP. There was a significantly higher proportion of short-term deaths in the EPP group versus the P/D group (percent mortality meta estimate; 4.5% vs 1.7%; p < 0.05). There was no statistically significant difference in 2-year mortality between the 2 groups, but there was significant heterogeneity.
CONCLUSIONS: The reanalysis of the large number of studies comparing P/D to EPP suggests that P/D is associated with a 2 ½-fold lower short-term mortality (perioperatively and within 30 days) than EPP. Pleurectomy decortication should therefore be preferred when technically feasible.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25534527     DOI: 10.1016/j.athoracsur.2014.09.056

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  50 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 2.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

4.  The impact of surgical approach on quality of life for pleural malignant mesothelioma.

Authors:  Rebecca M Schwartz; Alexis Watson; Andrea Wolf; Raja Flores; Emanuela Taioli
Journal:  Ann Transl Med       Date:  2017-06

5.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Authors:  Ori Wald; David J Sugarbaker
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

6.  Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.

Authors:  Omar Abdel-Rahman
Journal:  Strahlenther Onkol       Date:  2017-01-02       Impact factor: 3.621

7.  Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.

Authors:  Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; Kalliopi Athanassiadi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-29

Review 8.  Extended pleurectomy decortication: the current role.

Authors:  Rocco Bilancia; Marco Nardini; David A Waller
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 9.  Extrapleural pneumonectomy: still indicated?

Authors:  Andreas Domen; Lawek Berzenji; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2018-10

10.  Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.

Authors:  Alberto Sandri; Francesco Guerrera; Matteo Roffinella; Stefania Olivetti; Lorena Costardi; Alberto Oliaro; Pier Luigi Filosso; Paolo Olivo Lausi; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.